Continuing its mission to expand access to essential treatments, Camber Pharmaceuticals introduces abacavir and lamivudine tablets, USP, to its portfolio. The tablets (600 mg/300 mg) are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection and are supplied in 30 count bottles.